CUTIA-B(02487): CU-20401 (recombinant mutated collagenase) completes Phase II clinical trial for treating submental fat accumulation in China.
KeDi-B (02487) released an announcement that the group has completed the potential new drug CU-20401 (recombinant mutant jelly...
CUTIA-B (02487) announced that the group has completed Phase II clinical trials of a potential new drug, CU-20401 (recombinant mutated collagenase), for the treatment of submental fat accumulation in China. The clinical trials showed that CU-20401 demonstrated significant and robust therapeutic advantages with good safety.
The clinical trial was a multicenter, randomized, double-blind, and placebo-controlled trial designed to evaluate the efficacy and safety of CU-20401 in patients with moderate to severe submental fat accumulation. A total of 108 subjects were included in the trial and were randomly assigned to three groups in a 1:1:1 ratio - the low-dose CU-20401 group, the high-dose CU-20401 group, and the placebo control group. All three groups received a single dose and had a 100% compliance rate with medication.
Related Articles
HK Stock Market Move | ZTE Corporation (00763) once rose more than 10%, with its stock price increasing by over 80% so far this year. The company is intensifying its research and development of smart calculation-related products.
China Securities Co., Ltd.: The core contradiction in the current industry is anti-internal turnover, optimistic about the direction of new technology iteration in the photovoltaic industry.
HK Stock Market Move | CGN POWER (01816) continues to rise by over 4%, total electricity generation of nuclear power units in the first nine months increased by 2.67%, institutions are optimistic about the reduction of electricity price fluctuations in the company.
HK Stock Market Move | ZTE Corporation (00763) once rose more than 10%, with its stock price increasing by over 80% so far this year. The company is intensifying its research and development of smart calculation-related products.
China Securities Co., Ltd.: The core contradiction in the current industry is anti-internal turnover, optimistic about the direction of new technology iteration in the photovoltaic industry.
HK Stock Market Move | CGN POWER (01816) continues to rise by over 4%, total electricity generation of nuclear power units in the first nine months increased by 2.67%, institutions are optimistic about the reduction of electricity price fluctuations in the company.
